Vertex Pharmaceuticals (VRTX) Change in Account Payables (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Account Payables for 18 years, with the latest figure at $35.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 35.88% year-over-year to $35.6 million; the trailing twelve-month figure through Mar 2026 stood at $46.2 million (down 38.89% YoY), and the FY2025 full-year result was $36.8 million, down 25.66% from the prior year.
• Change in Account Payables for Q1 2026 stood at $35.6 million, down from $38.3 million in the prior quarter.
• The five-year high for Change in Account Payables was $159.9 million in Q4 2022, with the low at -$69.9 million in Q3 2022.
• Average Change in Account Payables over 5 years is $17.1 million, with a median of $9.2 million recorded in 2023.
• Year-over-year, Change in Account Payables plunged 3139.13% in 2022 and surged 26100.0% in 2025.
• Tracing VRTX's Change in Account Payables over 5 years: stood at $159.9 million in 2022, then tumbled by 119.89% to -$31.8 million in 2023, then soared by 126.42% to $8.4 million in 2024, then surged by 355.95% to $38.3 million in 2025, then slipped by 7.05% to $35.6 million in 2026.
• The last three Change in Account Payables figures came in at $35.6 million (Q1 2026), $38.3 million (Q4 2025), and -$35.3 million (Q3 2025), per Business Quant data.

Peer Comparison